|
Delayed
Nasdaq
09:30:01 2026-09-29 EDT
|
5-day change | 1st Jan Change | ||
| 4.870 USD | -0.20% |
|
-13.99% | -91.49% |
| 09-16 | Immutep refocuses efti development on head and neck cancer and soft tissue sarcoma | FI |
| 09-15 | Immutep's Drug Candidate Now Has Clearer Potential Development Path, Jefferies Says | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Biotechnology & Medical Research
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 49.06B | |||||
| 44.6B | |||||
| 43.24B | - | - | - | - | - |
| 41.73B | |||||
| 29.93B |
- Stock Market
- Stocks
- IMM Stock
- IMMP Stock
- Charts Immutep ADR
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
